<DOC>
	<DOCNO>NCT00335595</DOCNO>
	<brief_summary>The purpose study compare free time disease progression combination therapy capecitabine , oxaliplatin bevacizumab disease progression versus capecitabine , oxaliplatin bevacizumab 6 cycle follow bevacizumab disease progression premature drop study .</brief_summary>
	<brief_title>Study Bevacizumab Alone Combined With Capecitabine Oxaliplatin Support Therapy Metastatic Colorectal Cancer Patients</brief_title>
	<detailed_description>The purpose study compare free time disease progression combination therapy capecitabine , oxaliplatin bevacizumab disease progression versus capecitabine , oxaliplatin bevacizumab 6 cycle follow bevacizumab disease progression premature drop study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Written inform consent give . Patients able understand study request . Men woman &gt; = 18 year , hospitalize . Outpatients ECOG performance status ≤ 2 . Histologically confirm diagnosis colorectal cancer ( CRC ) patient metastasis . Presence least one detectable lesion accordance Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Life expectancy great 3 month . Men woman potentially fertile use effective contraceptive method Patients treat bevacizumab previously . Received systemic treatment previously treat advanced metastatic disease Adjuvant neoadjuvant treatment nonmetastatic disease allow , provide finish least 6 month initial study treatment . If patient treat adjuvant therapy previously , allow include study case disease progression treatment 6 month end treatment . If radiotherapy administer lesion select study , previous radiotherapy allow , unless progression injury document radiated field , long end treatment finish least 4 week study initiation . Previous surgical procedure stage IV disease allow . Previous malignancy adequately treat situ carcinoma uterine cervix , basal squamous cell carcinoma skin , study indication , unless diseasefree interval least 2 year . History evidence upon physical examination central nervous system History psychiatric disability judge investigator clinically significant precluding inform consent interfere compliance oral drug intake . Clinically significant cardiovascular disease ( active ) . Patients undergone myocardial infarction cerebrovascular accident 6 month prior randomisation exclude . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome inability take oral medication . Patients subject allogeneic transplant request immunotherapy . Bone fracture heal , wound severe ulcer . Known hemorrhagic diathesis coagulopathy . Uncontrolled severe intercurrent infection severe uncontrolled concomitant disease . Moderate severe renal impairment ( creatinine clearance &lt; 30 ml/min [ calculate accord CockroftGault formula ] serum creatinine ≥ 2 mg/dl 177 μmol/l ) . Any follow laboratory value : Absolute neutrophil count ( ANC ) ≤ 1.5 x 10^9/l . Platelet count ≤ 100 x 10^9/l . Hemoglobin ≤ 9 g/dl . International Normalized Ratio ( INR ) ≥ 1.5 . Total bilirubin ≥ 1.5 x upper limit normal ( ULN ) . ALT and/or AST ≥ 2.5 x ULN ≥ 5 x ULN ( case hepatic metastasis ) . Alkaline phosphatase &gt; 2.5 x ULN 5 x ULN ( case hepatic metastasis ) , &gt; 10 x ULN ( case bone metastasis ) . History unexpected serious adverse event fluoropyrimidine treatment know dihydropyrimidine dehydrogenase ( DPD ) deficiency . Patients subject major surgical procedure open biopsy ; patient significant traumatic injury 28 day initial study treatment ; patient major surgical procedure plan study period . Fine needle aspiration biopsy 7 day study initiation . Use full dose oral parenteral anticoagulant ( least 10 day initial study treatment ) thrombolytic agent . Low dose warfarin allow , INR ≤ 1.5 . Subjects require chronic use high dose aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory treatment ( know inhibit platelet function dos use treat chronic inflammatory disease ) . Pregnant lactating woman . Patients know allergy Chinese hamster ovary cell protein recombinant human humanize antibody ; excipients bevacizumab formulation ; study drug . Received investigational drug agent/procedure , i.e . participation another treatment trial within 30 day randomisation . Evidence another disease , metabolic malfunction , discovery physical examination clinical laboratory test result reasonable suspicion condition disease contraindicate investigational medicine use expose patient high risk treatment complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>capecitabine</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>